Thymosin Alpha-1
Also known as: Thymalfasin, Zadaxin, Ta1
Thymosin Alpha-1 (thymalfasin) is a peptide studied for immune-modulating roles and approved as a medicine in some countries. It is not generally approved for human use in Australia.
- Category
- Immune
- Reported half-life
- Reported to be approximately 2 hours in some studies; varies by preparation
- Common forms
- Lyophilised powder for reconstitution, Approved injectable medicine (thymalfasin) in some countries
- Research status
- Approved as a medicine (thymalfasin) in some countries and studied in clinical research; not generally approved for human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to be associated with immune-modulating activity in research
- Reported to be studied as an adjunct in certain infectious-disease research settings
- Reported to be studied in relation to immune-cell function
How it is reported to work
Thymosin Alpha-1 is a naturally occurring thymic peptide proposed to influence the maturation and function of certain immune cells, particularly T cells. These proposed mechanisms come from a mix of laboratory, animal and clinical research, and outcomes vary by context rather than being uniformly established.
Background
Thymosin Alpha-1 is a naturally occurring thymic peptide (marketed as thymalfasin in some regions) that has been studied for immune-modulating roles. This page is educational information, not medical advice, and the effects described below are reported claims, not established facts.
What the research shows
Research on Thymosin Alpha-1 spans laboratory, animal and clinical studies, with approved medicinal use (thymalfasin) in some countries. Evidence varies by setting, and approval status differs internationally.
| Evidence type | Status |
|---|---|
| Laboratory and animal studies | Present |
| Clinical research | Present in some indications |
| Approved medicine (some countries) | Yes (thymalfasin) |
| General Australian approval | Not generally approved |
What people use it for (reported)
Online, people report interest in Thymosin Alpha-1 in connection with immune support topics. These are reported claims, not validated outcomes for general use, and nothing here should be read as encouragement to use it.
Things to be aware of
Thymosin Alpha-1 is approved as a medicine in some countries but is not generally approved for human use in Australia. Grey-market preparations cannot be verified for purity or identity by sight, and self-use carries unquantified risk. If you have an immune-related health concern, the appropriate step is to speak with a qualified healthcare professional. This article does not recommend obtaining or using Thymosin Alpha-1. All effects described here remain reported claims, not established facts.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in research for immune-modulating activity
- Studied (as thymalfasin in some markets) in relation to certain infections and immune support
- Reported interest in supporting T-cell-related immune function
- Reported anecdotally for general immune resilience
Common side effects
- Reported injection-site redness, swelling or discomfort
- Reported transient fatigue or malaise
- Reported mild flu-like sensations
- Reported headache anecdotally
Rare / serious side effects
- Reported allergic or hypersensitivity-type reactions
- Reported joint pain or rash in some reports
- Reported concern that over-stimulating immune pathways could affect autoimmune conditions
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Thymosin Alpha-1. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-dosing for unproven infection or immune indications without medical oversight
- Reported use in autoimmune individuals where immune stimulation may be harmful
- Reported dose escalation beyond researched ranges seeking stronger effects
- Reported use of unverified grey-market product of unknown purity
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported onset is described over days to weeks, with no clinically established human timeline outside approved indications.
First effects
any reported subjective change within days
Noticeable change
reported immune or wellbeing changes over weeks
Clear results
reported cumulative changes after extended use; not clinically established
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Thymosin Alpha-1. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Reported as subcutaneous injection (mirroring the clinical thymalfasin route) |
|---|---|
| Typical reported dose | Reported around 1.6 mg per dose, matching the clinical thymalfasin dose |
| Frequency | Reported approximately twice per week in clinical thymalfasin use |
| Cycle length | Varies by context; reported clinical courses range from weeks to months depending on indication |
Reported reconstitution (mg → units)
Reported example: a 10 mg vial plus 5 mL bacteriostatic water gives 2 mg/mL. A reported 1.6 mg dose is about 0.8 mL, which is roughly 80 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported as subcutaneous courses given daily or several times weekly over weeks; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
Thymosin Alpha-1 is approved as a medicine in some countries but is not generally approved for human use in Australia. Grey-market product purity and identity cannot be verified by consumers, and self-use carries unquantified risk. Anyone with an immune-related health concern should consult a qualified healthcare professional.